May's 10 most-bought trusts
3rd June 2016 13:22
continues its impressive streak as the most popular investment trust with users on the Interactive Investor platform.
The trust, which is managed by James Anderson and is one of our sister magazine Money Observer's Rated Funds, has been the most-bought trust each month bar one since February 2014. The only time it was knocked off top spot was in April 2015, during
record-breaking £800 million launch., the multi-asset trust, took second place in May, while Woodford Patient Capital was the third most popular. The top three positions were unchanged from April, but there was plenty of movement in the rest of the top 10.
, managed by Nick Train, climbed three positions to take fourth place. Train holds a concentrated portfolio of around 30 stocks.
He favours businesses that have big brands.
, which makes Dove soap and Hellman's mayonnaise, is the biggest position in the portfolio, a 9.8% weighting.In fifth place, slipping one position, is
. The trust is favoured by income investors, thanks to long track record of increasing its dividend. In March the trust achieved the feat of raising its dividends every year for the past 50 years., which fell 10% in May, dropped one position to sixth. It is worth pointing out, however, that year-to-date the trust's share price has risen 30%, benefiting from that fact that gold has returned to favour in 2016.
, another specialist fund that tends to give investors a wild ride, took seventh place, gaining one place. The trust's share price rose 5.4% over the month of May, but over the past year has declined 23%.
, and complete the top 10. The latter has approached over a possible merger of the two trusts. RIT Capital Partners has until 27 June to make a formal offer.
May's 10 most-bought trusts | |||||
---|---|---|---|---|---|
Rank | Trust | AIC sector | Change since April | Total return 1m to 1 June (%) | Total return 3yr to 1 June (%) |
1 | Scottish Mortgage* | Global | - | 2.1 | 55.7 |
2 | Witan* | Global | - | 2.1 | 29.6 |
3 | Woodford Patient Capital | UK all companies | - | 0.9 | - |
4 | Finsbury Growth & Income* | UK equity income | 3 | 2 | 35.1 |
5 | City of London* | UK equity income | -1 | 1.1 | 19 |
6 | BlackRock World Mining* | Commodities and natural resources | -1 | -10 | -44.3 |
7 | Biotech Growth* | Biotechnology & healthcare | 1 | 5.4 | 53 |
8 | Jupiter European Opportunities* | Europe | 1 | 0 | 25.9 |
9 | Bankers* | Global | -3 | -0.5 | 15.2 |
10 | RIT Capital Partners* | Flexible investment | - | -3.6 | 36.3 |
*denotes Money Observer Rated Fund |
This article was originally published by our sister magazine Money Observer here.
This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Editor's Picks